Fátima Ortega

648 total citations
14 papers, 304 citations indexed

About

Fátima Ortega is a scholar working on Infectious Diseases, Molecular Biology and Epidemiology. According to data from OpenAlex, Fátima Ortega has authored 14 papers receiving a total of 304 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Infectious Diseases, 8 papers in Molecular Biology and 4 papers in Epidemiology. Recurrent topics in Fátima Ortega's work include Tuberculosis Research and Epidemiology (8 papers), Cancer therapeutics and mechanisms (4 papers) and Antibiotics Pharmacokinetics and Efficacy (3 papers). Fátima Ortega is often cited by papers focused on Tuberculosis Research and Epidemiology (8 papers), Cancer therapeutics and mechanisms (4 papers) and Antibiotics Pharmacokinetics and Efficacy (3 papers). Fátima Ortega collaborates with scholars based in Spain, United States and United Kingdom. Fátima Ortega's co-authors include Joaquín Rullás, Ulrika S. H. Simonsson, Chunli Chen, Lluís Ballell, Santiago Ferrer, Mariangela Biava, Robert H. Bates, Valentina Lucia La Rosa, Robert J. Young and Giovanna Poce and has published in prestigious journals such as PLoS ONE, Journal of Medicinal Chemistry and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Fátima Ortega

12 papers receiving 300 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fátima Ortega Spain 10 170 140 137 83 43 14 304
Mel Spigelman United States 6 272 1.6× 142 1.0× 171 1.2× 57 0.7× 22 0.5× 11 376
Allen Casey United States 10 250 1.5× 199 1.4× 167 1.2× 104 1.3× 30 0.7× 10 405
Jitendar Reddy India 7 153 0.9× 116 0.8× 80 0.6× 58 0.7× 34 0.8× 9 255
Yoonae Ko South Korea 9 123 0.7× 143 1.0× 71 0.5× 110 1.3× 16 0.4× 14 307
Kawaljit Singh South Africa 13 84 0.5× 131 0.9× 46 0.3× 192 2.3× 41 1.0× 21 354
Prabhakar Reddy United States 5 183 1.1× 97 0.7× 83 0.6× 33 0.4× 18 0.4× 10 318
Michael Goodwin United States 10 366 2.2× 290 2.1× 210 1.5× 153 1.8× 50 1.2× 14 579
S. Stokes United States 12 133 0.8× 284 2.0× 85 0.6× 163 2.0× 47 1.1× 18 436
David Barros-Aguirre Spain 13 253 1.5× 194 1.4× 165 1.2× 102 1.2× 21 0.5× 19 410
Stanislav Huszár Slovakia 10 256 1.5× 298 2.1× 115 0.8× 169 2.0× 16 0.4× 12 451

Countries citing papers authored by Fátima Ortega

Since Specialization
Citations

This map shows the geographic impact of Fátima Ortega's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fátima Ortega with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fátima Ortega more than expected).

Fields of papers citing papers by Fátima Ortega

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fátima Ortega. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fátima Ortega. The network helps show where Fátima Ortega may publish in the future.

Co-authorship network of co-authors of Fátima Ortega

This figure shows the co-authorship network connecting the top 25 collaborators of Fátima Ortega. A scholar is included among the top collaborators of Fátima Ortega based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fátima Ortega. Fátima Ortega is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Kavanagh, Madeline E., Kirsty J. McLean, M. Snee, et al.. (2025). Fragment-Based Development of Small Molecule Inhibitors Targeting Mycobacterium tuberculosis Cholesterol Metabolism. Journal of Medicinal Chemistry. 68(14). 14416–14441.
2.
Ganapathy, Uday S., Fátima Ortega, Joël Lelièvre, et al.. (2021). A Leucyl-tRNA Synthetase Inhibitor with Broad-Spectrum Antimycobacterial Activity. Antimicrobial Agents and Chemotherapy. 65(5). 31 indexed citations
3.
Borthwick, Alan D., Carlos Alemparte, Ian D. Wall, et al.. (2020). Mycobacterium tuberculosis Decaprenylphosphoryl-β-d-ribose Oxidase Inhibitors: Expeditious Reconstruction of Suboptimal Hits into a Series with Potent in Vivo Activity. Journal of Medicinal Chemistry. 63(5). 2557–2576. 28 indexed citations
4.
Moure, Abraham L., Gagandeep Narula, Flavia Sorrentino, et al.. (2020). MymA Bioactivated Thioalkylbenzoxazole Prodrug Family Active against Mycobacterium tuberculosis. Journal of Medicinal Chemistry. 63(9). 4732–4748. 9 indexed citations
5.
Chen, Chunli, Fátima Ortega, Joaquín Rullás, et al.. (2017). The multistate tuberculosis pharmacometric model: a semi-mechanistic pharmacokinetic-pharmacodynamic model for studying drug effects in an acute tuberculosis mouse model. Journal of Pharmacokinetics and Pharmacodynamics. 44(2). 133–141. 20 indexed citations
6.
Chen, Chunli, Sebastian G. Wicha, Gerjo J. de Knegt, et al.. (2017). Assessing Pharmacodynamic Interactions in Mice Using the Multistate Tuberculosis Pharmacometric and General Pharmacodynamic Interaction Models. CPT Pharmacometrics & Systems Pharmacology. 6(11). 787–797. 24 indexed citations
7.
Chen, Chunli, et al.. (2016). Population pharmacokinetics, optimised design and sample size determination for rifampicin, isoniazid, ethambutol and pyrazinamide in the mouse. European Journal of Pharmaceutical Sciences. 93. 319–333. 11 indexed citations
8.
9.
Kumar, Anuradha, Gonzalo Colmenarejo, Esther Pérez‐Herrán, et al.. (2015). A Focused Screen Identifies Antifolates with Activity on Mycobacterium tuberculosis. ACS Infectious Diseases. 1(12). 604–614. 23 indexed citations
10.
Díaz-González, Rosario, João Seixas, Emanuele Amata, et al.. (2014). Identification and Characterization of Hundreds of Potent and Selective Inhibitors of Trypanosoma brucei Growth from a Kinase-Targeted Library Screening Campaign. PLoS neglected tropical diseases. 8(10). e3253–e3253. 40 indexed citations
11.
Poce, Giovanna, Robert H. Bates, Salvatore Alfonso, et al.. (2013). Improved BM212 MmpL3 Inhibitor Analogue Shows Efficacy in Acute Murine Model of Tuberculosis Infection. PLoS ONE. 8(2). e56980–e56980. 77 indexed citations
12.
Ortega, Fátima, Elena Suárez, John C. Lukas, et al.. (2005). Pharmacokinetic–Pharmacodynamic Modeling of the Hydroxy Lerisetron Metabolite L6-OH in Rats: An Integrated Parent–Metabolite Model. Pharmaceutical Research. 22(11). 1769–1782. 3 indexed citations
13.
Ortega, Fátima, et al.. (2002). Historia Clínica: Nueva metodología para el registro de los datos. 110(3). 347–349.
14.
Carrillo, Luisa, Dolores Badı́a, Esther Domı́nguez, Fátima Ortega, & Imanol Tellitu. (1998). A contribution to the asymmetric synthesis of isoquinolines: Concise stereoselective approach to (3S,4S)-6,7-dimethoxy-4-hydroxy-3-phenyl-1,2,3,4-tetrahydroisoquinoline. Tetrahedron Asymmetry. 9(1). 151–155. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mel Spigelman Breakdown of academic impact, for papers by Allen Casey Breakdown of academic impact, for papers by Jitendar Reddy Breakdown of academic impact, for papers by Yoonae Ko Breakdown of academic impact, for papers by Kawaljit Singh Breakdown of academic impact, for papers by Prabhakar Reddy Breakdown of academic impact, for papers by Michael Goodwin Breakdown of academic impact, for papers by S. Stokes Breakdown of academic impact, for papers by David Barros-Aguirre Breakdown of academic impact, for papers by Stanislav Huszár
Rankless by CCL
2026